Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 06:32 PM UTC

Segments 13-16 report that Moderna and Merck's personalized cancer treatment succeeded in a Phase 3 trial, with patients receiving the custom shot plus Keytruda going longer without cancer recurrence. Moderna shares closed 177% higher, indicating a material positive catalyst for the company.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 06:27 PM UTC

Moderna's Phase 3 cancer vaccine trial succeeded, showing improved recurrence-free survival when combined with Keytruda, leading to a 177% stock surge. This is a material positive catalyst for Moderna.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 06:22 PM UTC

Segments 13-17 report that Moderna and Merck's personalized cancer treatment succeeded in a Phase 3 trial, showing longer recurrence-free survival compared to Keytruda alone. This is a material positive catalyst for Moderna, and the stock surged 177% on the news.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 06:17 PM UTC

Moderna's Phase 3 trial success for its personalized cancer vaccine represents a significant positive catalyst, with the stock surging 177% on the news. The treatment demonstrated improved recurrence-free survival compared to Keytruda alone, and the company is exploring nine cancer types, suggesting broad potential.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 06:12 PM UTC

Moderna reported positive Phase 3 results for its personalized cancer vaccine, a major clinical milestone that led to a 177% stock surge. This is a material positive catalyst for the company.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 06:07 PM UTC

Moderna reported positive Phase 3 results for its personalized cancer vaccine, a significant positive catalyst for the company's fundamentals and stock price.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 06:02 PM UTC

Moderna's Phase 3 cancer vaccine trial succeeded, with patients receiving the custom shot plus Keytruda going longer without cancer recurrence. This is a material positive catalyst, and shares surged 177% on the news.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 05:57 PM UTC

Moderna's Phase 3 cancer vaccine trial succeeded, with shares closing 177% higher, representing a material positive catalyst for the company.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 05:52 PM UTC

Moderna reported positive Phase 3 results for its personalized cancer vaccine, leading to a 177% surge in its stock price. This is a material positive catalyst indicating improved expected fundamentals.

Source published Aug 23, 2026, 09:29 PM UTC · Operation recorded Aug 27, 2026, 05:47 PM UTC

Segments 13-16 report that Moderna and Merck's personalized cancer treatment succeeded in a Phase 3 trial, with patients going longer without cancer recurrence, and Moderna shares closed 177% higher. This is a material positive catalyst for Moderna.